[ad_1]
The study involved 7,000 members of the health staff at the hospital, which is the largest in Israel. Reports Sky News.
The study, which was also published in the acclaimed research journal The Lancet, concludes that the crown vaccine from Pfizer and Biontech is 85 percent effective after the first dose.
NIPH: significantly inhibits infection
75 to 85 percent
Pfizer’s corona vaccine is given in two doses, every few weeks, and is the first to be used in Norway, among other places. Israel has secured a large volume of the vaccine and has already come a relatively long way in the mass vaccination process of the population.
Healthcare personnel who participated in the current study received the first dose in January, and 15 to 28 days after the vaccine was administered, researchers saw an 85 percent reduction in symptomatic COVID-19 among those vaccinated.
Including people without symptoms, the reduction was 75 percent.
– This is the first real-world evidence of the vaccine’s effectiveness after the first dose, says Professor Eyal Leshem, an infectious disease expert and director of the hospital’s Department of Travel and Tropical Medicine.
Eliminate vaccine confusion
More positive
The Sheba Medical Center study, which is also peer-reviewed, paints a more positive picture of the effect of the vaccine than an Israeli study published in January. This study found that among 200,000 patients, positive tests were reduced by 33 percent 14 days after the first dose was established.
Following the outbreak of mutated variants of the coronavirus in South Africa and the United Kingdom, there have been fears that coronavirus vaccines will be less effective against these variants, especially against the South African.
On Thursday, Pfizer and Biontech confirmed that their corona vaccine also works against the South African variant, NTB writes.
– There is no clinical evidence that the South African virus variant overlooks the protection of the coronary vaccine, the manufacturers said in a joint statement Thursday.
However, a study published in the New England Journal of Medicine shows that although the Pfizer and Biontech vaccine works against the South African variant, its efficacy is weaker than that of the common coronavirus.
